304 North Cardinal St.
Dorchester Center, MA 02124
304 North Cardinal St.
Dorchester Center, MA 02124
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. World most cancers statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 international locations. CA Most cancers J Clin. 2018;68(6):394–424.
Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–14.
Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380(15):1450–62.
Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Prim. 2021;7(1):6.
Zhu AX, Rosmorduc O, Evans TR, Ross PJ, Santoro A, Carrilho FJ, et al. SEARCH: a part III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in sufferers with superior hepatocellular carcinoma. J Clin Oncol. 2015;33(6):559–66.
Kudo M, Finn RS, Qin S, Han KH, Ikeda Ok, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line therapy of sufferers with unresectable hepatocellular carcinoma: a randomised part 3 non-inferiority trial. Lancet. 2018;391(10126):1163–73.
Zupancic S, Lavric Z, Kristl J. Stability and solubility of trans-resveratrol are strongly influenced by pH and temperature. Eur J Pharm Biopharm. 2015;93:196–204.
Hu Y, Wang S, Wu X, Zhang J, Chen R, Chen M, et al. Chinese language natural medicine-derived compounds for most cancers remedy: a give attention to hepatocellular carcinoma. J Ethnopharmacol. 2013;149(3):601–12.
Cheng Y, Zhao P, Wu S, Yang T, Chen Y, Zhang X, et al. Cisplatin and curcumin co-loaded nano-liposomes for the therapy of hepatocellular carcinoma. Int J Pharm. 2018;545(1–2):261–73.
Najafi M, Mortezaee Ok, Rahimifard M, Farhood B, Haghi-Aminjan H. The function of curcumin/curcuminoids throughout gastric most cancers chemotherapy: a scientific overview of non-clinical examine. Life Sci. 2020;257: 118051.
Ramezani Farani M, Azarian M, Heydari Sheikh Hossein H, Abdolvahabi Z, Mohammadi Abgarmi Z, Moradi A, et al. Folic acid-adorned curcumin-loaded iron oxide nanoparticles for cervical most cancers. ACS Appl Bio Mater. 2022;5(3):1305–18.
Li J, Wei H, Liu Y, Li Q, Guo H, Guo Y, et al. Curcumin inhibits hepatocellular carcinoma through regulating miR-21/TIMP3 axis. Evid Primarily based Complement Altern Med. 2020;2020:2892917.
Darvesh AS, Aggarwal BB, Bishayee A. Curcumin and liver most cancers: a overview. Curr Pharm Biotechnol. 2012;13(1):218–28.
Xue YQ, Di JM, Luo Y, Cheng KJ, Wei X, Shi Z. Resveratrol oligomers for the prevention and therapy of cancers. Oxid Med Cell Longev. 2014;2014: 765832.
Amini P, Nodooshan SJ, Ashrafizadeh M, Eftekhari SM, Aryafar T, Khalafi L, et al. Resveratrol induces apoptosis and attenuates proliferation of MCF-7 cells together with radiation and hyperthermia. Curr Mol Med. 2021;21(2):142–50.
Vernousfaderani EK, Akhtari N, Rezaei S, Rezaee Y, Shiranirad S, Mashhadi M, et al. Resveratrol and colorectal most cancers: a molecular method to scientific researches. Curr Prime Med Chem. 2021;21(29):2634–46.
Qian W, Xiao Q, Wang L, Qin T, Xiao Y, Li J, et al. Resveratrol slows the tumourigenesis of pancreatic most cancers by inhibiting NFkappaB activation. Biomed Pharmacother. 2020;127:110116.
Zaffaroni N, Beretta GL. Resveratrol and prostate most cancers: the ability of phytochemicals. Curr Med Chem. 2021;28(24):4845–62.
Track F, Zhang Y, Pan Z, Zhang Q, Lu X, Huang P. Resveratrol inhibits the migration, invasion and epithelial-mesenchymal transition in liver most cancers cells by way of up- miR-186–5p expression. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2021;50(5):582–90.
Kohandel Z, Farkhondeh T, Aschner M, Pourbagher-Shahri AM, Samarghandian S. STAT3 pathway as a molecular goal for resveratrol in breast most cancers therapy. Most cancers Cell Int. 2021;21(1):468.
Rauf A, Imran M, Butt MS, Nadeem M, Peters DG, Mubarak MS. Resveratrol as an anti-cancer agent: a overview. Crit Rev Meals Sci Nutr. 2018;58(9):1428–47.
Cheuk IW, Chen J, Siu M, Ho JC, Lam SS, Shin VY, et al. Resveratrol enhanced chemosensitivity by reversing macrophage polarization in breast most cancers. Clin Transl Oncol. 2022;24(5):854–63.
Bostan M, Mihaila M, Petrica-Matei GG, Radu N, Hainarosie R, Stefanescu CD, et al. Resveratrol modulation of apoptosis and cell cycle response to cisplatin in head and neck most cancers cell traces. Int J Mol Sci. 2021. https://doi.org/10.3390/ijms22126322.
Abadi AJ, Mirzaei S, Mahabady MK, Hashemi F, Zabolian A, Hashemi F, et al. Curcumin and its derivatives in most cancers remedy: potentiating antitumor exercise of cisplatin and lowering unwanted effects. Phytother Res. 2022;36(1):189–213.
Muhanmode Y, Wen MK, Maitinuri A, Shen G. Curcumin and resveratrol inhibit chemoresistance in cisplatin-resistant epithelial ovarian most cancers cells through focusing on P13K pathway. Hum Exp Toxicol. 2021;40(12_suppl):S861–8.
Guo W, Wu X, Li Y, Gao J, Wang F, Jin Y, et al. Analysis of biophysical in addition to biochemical potential of curcumin and resveratrol throughout prostate most cancers. J Drug Goal. 2020;28(1):41–5.
Carlson LJ, Cote B, Alani AW, Rao DA. Polymeric micellar co-delivery of resveratrol and curcumin to mitigate in vitro doxorubicin-induced cardiotoxicity. J Pharm Sci. 2014;103(8):2315–22.
Enviornment A, Romeo MA, Benedetti R, Masuelli L, Bei R, Gilardini Montani MS, et al. New Insights into curcumin- and resveratrol-mediated anti-cancer results. Prescribed drugs. 2021. https://doi.org/10.3390/ph14111068.
Patra S, Pradhan B, Nayak R, Behera C, Rout L, Jena M, et al. Chemotherapeutic efficacy of curcumin and resveratrol in opposition to most cancers: Chemoprevention, chemoprotection, drug synergism and scientific pharmacokinetics. Semin Most cancers Biol. 2021;73:310–20.
Meng L, Chu X, Xing H, Liu X, Xin X, Chen L, et al. Enhancing glioblastoma therapeutic outcomes through doxorubicin-loaded nanomicelles modified with borneol. Int J Pharm. 2019;567: 118485.
Huang X, Li M, Bruni R, Messa P, Cellesi F. The impact of thermosensitive liposomal formulations on loading and launch of excessive molecular weight biomolecules. Int J Pharm. 2017;524(1–2):279–89.
Li R, He Y, Zhang S, Qin J, Wang J. Cell membrane-based nanoparticles: a brand new biomimetic platform for tumor prognosis and therapy. Acta Pharmaceut Sin B. 2018;8(1):14–22.
Liu W, Wei F, Ye A, Tian M, Han J. Kinetic stability and membrane construction of liposomes throughout in vitro toddler intestinal digestion: impact of ldl cholesterol and lactoferrin. Meals Chem. 2017;230:6–13.
Reddy BP, Yadav HK, Nagesha DK, Raizaday A, Karim A. Polymeric micelles as novel carriers for poorly soluble medicine–a overview. J Nanosci Nanotechnol. 2015;15(6):4009–18.
de Ghellinck A, Shen C, Fragneto G, Klosgen B. Probing the place of resveratrol in lipid bilayers: a neutron reflectivity examine. Colloids Surf B. 2015;134:65–72.
Karewicz A, Bielska D, Gzyl-Malcher B, Kepczynski M, Lach R, Nowakowska M. Interplay of curcumin with lipid monolayers and liposomal bilayers. Colloids Surf B. 2011;88(1):231–9.
Wang H, Xie H, Wu J, Wei X, Zhou L, Xu X, et al. Construction-based rational design of prodrugs to allow their mixture with polymeric nanoparticle supply platforms for enhanced antitumor efficacy. Angew Chem. 2014;53(43):11532–7.
Johnsen KB, Burkhart A, Thomsen LB, Andresen TL, Moos T. Concentrating on the transferrin receptor for mind drug supply. Prog Neurobiol. 2019;181: 101665.
Rastegar R, Akbari Javar H, Khoobi M, Dehghan Kelishadi P, Hossein Yousefi G, Doosti M, et al. Analysis of a novel biocompatible magnetic nanomedicine primarily based on beta-cyclodextrin, loaded doxorubicin-curcumin for overcoming chemoresistance in breast most cancers. Artif Cells Nanomed Biotechnol. 2018;46(sup2):207–16.
Yang Z, Liu J, Lu Y. Doxorubicin and CDCUR inclusion complicated coloaded in thermosensitive hydrogel PLGAPEGPLGA localized administration for osteosarcoma. Int J Oncol. 2020;57(2):433–44.
Rafati N, Zarrabi A, Caldera F, Trotta F, Ghias N. Pyromellitic dianhydride crosslinked cyclodextrin nanosponges for curcumin managed launch; formulation, physicochemical characterization and cytotoxicity investigations. J Microencapsul. 2019;36(8):715–27.
Yang Z, Wang J, Liu S, Li X, Miao L, Yang B, et al. Defeating relapsed and refractory malignancies by way of a nano-enabled mitochondria-mediated respiratory inhibition and harm pathway. Biomaterials. 2020;229: 119580.
Li Y, Hu Y, Xiao J, Liu G, Li X, Zhao Y, et al. Investigation of SP94 peptide as a particular probe for hepatocellular carcinoma imaging and remedy. Sci Rep. 2016;6:33511.
Ashley CE, Carnes EC, Phillips GK, Padilla D, Durfee PN, Brown PA, et al. The focused supply of multicomponent cargos to most cancers cells by nanoporous particle-supported lipid bilayers. Nat Mater. 2011;10(5):389–97.
Toita R, Murata M, Tabata S, Abe Ok, Narahara S, Piao JS, et al. Growth of human hepatocellular carcinoma cell-targeted protein cages. Bioconjug Chem. 2012;23(7):1494–501.
Zhu AX, Duda DG, Sahani DV, Jain RK. HCC and angiogenesis: potential targets and future instructions. Nat Rev Clin Oncol. 2011;8(5):292–301.
Hollis CP, Weiss HL, Leggas M, Evers BM, Gemeinhart RA, Li T. Biodistribution and bioimaging research of hybrid paclitaxel nanocrystals: classes realized of the EPR impact and image-guided drug supply. J Management Launch. 2013;172(1):12–21.
Khan H, Ullah H, Nabavi SM. Mechanistic insights of hepatoprotective results of curcumin: therapeutic updates and future prospects. Meals Chem Toxicol. 2019;124:182–91.
Circu ML, Aw TY. Reactive oxygen species, mobile redox methods, and apoptosis. Free Radical Biol Med. 2010;48(6):749–62.
Bishayee A, Politis T, Darvesh AS. Resveratrol within the chemoprevention and therapy of hepatocellular carcinoma. Most cancers Deal with Rev. 2010;36(1):43–53.
Fornari F, Pollutri D, Patrizi C, La Bella T, Marinelli S, Casadei Gardini A, et al. In hepatocellular carcinoma miR-221 modulates sorafenib resistance by way of inhibition of caspase-3-mediated apoptosis. Clin Most cancers Res. 2017;23(14):3953–65.
Zhou T, Liang X, Wang P, Hu Y, Qi Y, Jin Y, et al. A hepatocellular carcinoma focusing on nanostrategy with hypoxia-ameliorating and photothermal skills that, mixed with immunotherapy, inhibits metastasis and recurrence. ACS Nano. 2020;14(10):12679–96.
Chou T-C, Martin N. CompuSyn software program for drug mixtures and for normal dose-effect evaluation, and person’s information. Paramus: ComboSyn, Inc.; 2007.
Cote B, Carlson LJ, Rao DA, Alani AWG. Combinatorial resveratrol and quercetin polymeric micelles mitigate doxorubicin induced cardiotoxicity in vitro and in vivo. J Management Launch. 2015;213:128–33.
Pedre B, Barayeu U, Ezerina D, Dick TP. The mechanism of motion of N-acetylcysteine (NAC): the rising function of H2S and sulfane sulfur species. Pharmacol Ther. 2021;228: 107916.
Zhu L, Yuan H, Guo C, Lu Y, Deng S, Yang Y, et al. Zearalenone induces apoptosis and necrosis in porcine granulosa cells through a caspase-3- and caspase-9-dependent mitochondrial signaling pathway. J Cell Physiol. 2012;227(5):1814–20.
Zhang C, Xin L, Li J, Cao J, Solar Y, Wang X, et al. Steel-organic framework (MOF)-based ultrasound-responsive dual-sonosensitizer nanoplatform for hypoxic most cancers remedy. Adv Healthc Mater. 2022;11(2): e2101946.